Regulatory

Regulatory

Navamedic ASA – Additional underwriting commitments in the Rights Issue

Navamedic ASA: First approval of the medical device OraFID® as primary package for a pharmaceutical product

Navamedic ASA – Investor presentation regarding the acquisition of the business of dne pharma AS

Navamedic ASA: Notice of extraordinary general meeting on 14 July 2025 in connection with a contemplated rights issue

Navamedic ASA: Key information relating to the Rights Issue

Navamedic ASA expands into addiction treatment through the acquisition of the business of dne pharma and announces a partially underwritten rights issue